Vaccines for epidemic infections and the role of CEPI
Open Access
- 4 April 2017
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (12) , 2755-2762
Abstract
The author reviews the foundation of the Coalition for Epidemic Preparedness and Innovations and the choices it has made for funding of vaccine development against epidemic diseases. He comments on those decisions as well as proposing how CEPI could remain relevant for the long term.Keywords
This publication has 69 references indexed in Scilit:
- Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in miceAntiviral Research, 2017
- CD8 + T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory SyndromeJournal of Virology, 2017
- Chikungunya Virus Vaccines: Viral Vector–Based Approaches: Table 1.The Journal of Infectious Diseases, 2016
- Chikungunya: Its History in Africa and Asia and Its Spread to New Regions in 2013–2014The Journal of Infectious Diseases, 2016
- MERS-CoV vaccine candidates in development: The current landscapeVaccine, 2016
- Status of vaccine research and development of vaccines for Nipah virusVaccine, 2016
- An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camelsScience, 2016
- Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory DiseasesViruses, 2014
- Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trialsExpert Review of Vaccines, 2013
- Live Attenuated Measles Vaccine as a Potential Multivalent Pediatric Vaccination VectorViral Immunology, 2005